ERBB2 and cancer: Trastuzumab, also known as Herceptin, Ogivri, or Herzuma, is an mAb targeting epidermal growth factor receptor 2 (HER2), the first recombinant antibody to be commercially approved as cancer drug by the FDA in 1997.